BAM15

What it is

BAM15 is a synthetic small-molecule mitochondrial protonophore uncoupler, not a peptide. It carries protons across the inner mitochondrial membrane, allowing part of the proton gradient to bypass ATP synthase. The result is lower calorie-to-ATP efficiency: mitochondria must oxidize more fuel to meet the same energy demand.

Why the fat-loss mechanism is interesting

BAM15 does not depend on appetite suppression. Its primary mechanism directly increases energy expenditure by reducing mitochondrial efficiency, while AMPK activation appears downstream of that energy stress. The original cell work found a broader useful respiratory range and less plasma-membrane depolarization than the laboratory uncoupler FCCP.

The animal evidence

Across several mouse models, BAM15 increased energy expenditure and fat oxidation, reduced body fat and liver triglycerides, improved glucose control and insulin sensitivity, and generally preserved lean mass without suppressing food intake. A 2025 comparison of 15 uncouplers found that BAM15 produced the best overall combination of body-weight, glucose, and fatty-liver effects in diabetic mice.

Exposure context

The foundational obesity studies administered BAM15 to mice in food, creating repeated exposure across the feeding period. Mouse oral pharmacokinetics showed a short half-life, but there are no living-human pharmacokinetic or dose-ranging data. The three timing windows recorded here are therefore a personal experiment structure, not a clinically validated translation of the animal studies.

Human evidence and safety boundary

No published trial has administered systemic BAM15 to living humans, and ClinicalTrials.gov lists no BAM15 studies. The mouse experiments reported no meaningful change in body temperature or common short-term toxicity markers at the studied exposures, but they do not establish a human therapeutic window. Mitochondrial uncoupling is the intended mechanism, so temperature, heart rate, exercise tolerance, and recovery are relevant observations in this record.

Sources

• Kenwood et al., Molecular Metabolism 2014 — discovery, mitochondrial selectivity, respiratory activity, and comparison with FCCP.
• Alexopoulos et al., Nature Communications 2020 — reversal of diet-induced obesity, liver-fat reduction, insulin sensitivity, oral pharmacokinetics, and short-term mouse safety markers.
• Axelrod et al., EMBO Molecular Medicine 2020 — energy expenditure, tissue distribution, AMPK signaling, body composition, and glycemic control in mice.
• Murphy et al., Molecular Metabolism 2025 — head-to-head comparison of 15 mitochondrial uncouplers in cells and diabetic mice.
• ClinicalTrials.gov: BAM15 — current registered human-trial search.

Start and current protocol

I started BAM15 on August 24, 2026 at 200 mg/day, split into 100 mg after waking and 100 mg before sleep. The exposure was titrated upward and is now 1,500 mg/day: 500 mg post-workout, 500 mg after the daily large meal, and 500 mg before sleep. The first dose moved from after waking to post-workout to prevent low energy during training. This records my use; it is not a suggested dose, timing strategy, or protocol.

Primary outcome

This is primarily a fat-loss experiment. The useful result would be a clear improvement in the weight trend that is large enough to matter within the surrounding diet, training, and compound routine.

What I will watch

I will track morning weight, temperature, resting heart rate, training performance, recovery, sleep, perceived heat or sweating, fatigue, appetite, and any other noticeable effect. The experiment begins as an observation period rather than assuming that a perceptible acute effect is required.

Duration and status

The initial experiment is expected to run for approximately one month, with the option to continue into a second month if the result appears useful. The experiment is active, and no outcome has been recorded yet.